251 CONSUMERS ROAD, TORONTO, A6
Market cap: $4.4M (11/24/2025)
Price: $1.71
Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition Pending Final Clearance from SEC
Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
Aptose Biosciences Enters Definitive Arrangement Agreement with Hanmi
Announces Arrangement Agreement for Acquisition
Reports Third Quarter 2025 Results
Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
Q3
Q2
Q1
FY 2023 amended
FY 2023
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
Additional Proxy Materials
Definitive Proxy Statement
PRER14A
PRE 14A
Notification Filed by a National Security Exchange
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
PREM14A